Alveolar soft part sarcomas: Molecular pathogenesis and implications for novel targeted therapies

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Mitton, Bryan ^a   Federman, Noah ^a,b  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARQULE; BEVACIZUMAB; CD147 ANTIGEN; CEDIRANIB; CYCLOPHOSPHAMIDE; DESMIN; DOXORUBICIN; GLUCOSE TRANSPORTER 4; LYMPHOID ENHANCER FACTOR 1; MONOCARBOXYLATE TRANSPORTER 1; PERIFOSINE; SMAD3 PROTEIN; SORAFENIB; SUNITINIB; TIVANTINIB; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG; VINCRISTINE;

AGE; ALVEOLAR SOFT PART SARCOMA; AUTOPHOSPHORYLATION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME 17; CHROMOSOME TRANSLOCATION; CLEAR CELL CARCINOMA; ELECTRON MICROSCOPY; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SEX DIFFERENCE; TONGUE; TUMOR VOLUME; X CHROMOSOME;

EID: 84861075560     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/428789     Document Type: Review

References (63)

1. Portera C. A., Ho V., Patel S. R., Hunt K. K., Feig B. W., Respondek P. M., Yasko A. W., Benjamin R. S., Pollock R. E., Pisters P. W. T., Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution Cancer 2001 91 3 585 591 (Pubitemid 32105705)
2. Lieberman P. H., Brennan M. F., Kimmel M., Erlandson R. A., Garin-Chesa P., Flehinger B. Y., Alveolar soft-part sarcoma. A clinico-pathologic study of half a century Cancer 1989 63 1 1 13 (Pubitemid 19031974)
3. Ordez N. G., Mackay B., Alveolar soft-part sarcoma: a review of the pathology and histogenesis Ultrastructural Pathology 1998 22 4 275 292
4. Ordez N. G., Alveolar soft part sarcoma: a review and update Advances in Anatomic Pathology 1999 6 3 125 139
5. Casanova M., Ferrari A., Bisogno G., Cecchetto G., Basso E., De Bernardi B., Indolfi P., Fossati Bellani F., Carli M., Alveolar soft part sarcoma in children and adolescents: a report from the soft-tissue sarcoma italian cooperative group Annals of Oncology 2000 11 11 1445 1449
6. Kayton M. L., Meyers P., Wexler L. H., Gerald W. L., LaQuaglia M. P., Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults Journal of Pediatric Surgery 2006 41 1 187 193 (Pubitemid 43067515)
7. Ogose A., Morita T., Hotta T., Kobayashi H., Otsuka H., Hirata Y., Yoshida S., Brain metastases in musculoskeletal sarcomas Japanese Journal of Clinical Oncology 1999 29 5 245 247
8. Salvati M., Cervoni L., Caruso R., Gagliardi F. M., Delfini R., Sarcoma metastatic to the brain: a series of 15 cases Surgical Neurology 1998 49 4 441 444 (Pubitemid 28153025)
9. Evans H. L., Alveolar soft-part sarcoma. A study of 13 typical examples and one with a histologically atypical component Cancer 1985 55 4 912 917 (Pubitemid 15173534)
10. Lorigan J. G., O'Keeffe F. N., Evans H. L., Wallace S., The radiologic manifestations of alveolar soft-part sarcoma American Journal of Roentgenology 1989 153 2 335 339 (Pubitemid 19198018)
11. Christopherson W. M., Foote F. W., Stewart F. W., Alveolar soft-part sarcomas; structurally characteristic tumors of uncertain histogenesis Cancer 1952 5 1 100 111
12. Tallini G., Parham D. M., Dias P., Cordon-Cardo C., Houghton P. J., Rosai J., Myogenic regulatory protein expression in adult soft tissue sarcomas: a sensitive and specific marker of skeletal muscle differentiation American Journal of Pathology 1994 144 4 693 701 (Pubitemid 24172058)
13. Wang N. P., Bacchi C. E., Jiang J. J., McNutt M. A., Gown A. M., Does alveolar soft-part sarcoma exhibit skeletal muscle differentiation? An immunocytochemical and biochemical study of myogenic regulatory protein expression Modern Pathology 1996 9 5 496 506 (Pubitemid 26170424)
14. Rosai J., Dias P., Parham D. M., Shapiro D. N., Houghton P., MyoD1 protein expression in alveolar soft part sarcoma as confirmatory evidence of its skeletal muscle nature American Journal of Surgical Pathology 1991 15 10 974 981
15. Gmez J. A., Amin M. B., Ro J. Y., Linden M. D., Lee M. W., Zarbo R. J., Immunohistochemical profile of Myogenin and MyoD1 does not support skeletal muscle lineage in alveolar soft part sarcoma: a study of 19 tumors Archives of Pathology and Laboratory Medicine 1999 123 6 503 507 (Pubitemid 29255027)
16. Nielsen G. P., Oliva E., Young R. H., Rosenberg A. E., Dickersin G. R., Scully R. E., Alveolar soft-part sarcoma of the female genital tract: a report of nine cases and review of the literature International Journal of Gynecological Pathology 1995 14 4 283 292
17. Yagihashi S., Yagihashi N., Hase Y., Nagai K., Alguacil-Garcia A., Primary alveolar soft-part sarcoma of stomach American Journal of Surgical Pathology 1991 15 4 399 406
18. Wu J., Brinker D. A., Haas M., Montgomery E. A., Argani P., Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy International Journal of Surgical Pathology 2005 13 1 81 85 (Pubitemid 40224102)
19. Fanburg-Smith J. C., Miettinen M., Folpe A. L., Weiss S. W., Childers E. L. B., Lingual alveolar soft part sarcoma; 14 cases: novel clinical and morphological observations Histopathology 2004 45 5 526 537 (Pubitemid 39524328)
20. Smetana H., Scott W., Malignant tumors of nonchromaffin paraganglia Military Surgery 1951 109 4 330 349
21. Ladanyi M., Antonescu C. R., Drobnjak M., Baren A., Lui M. Y., Golde D. W., Cordon-Cardo C., The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147 American Journal of Pathology 2002 160 4 1215 1221 (Pubitemid 34411625)
22. Ladanyi M., Lui M. Y., Antonescu C. R., Krause-Boehm A., Meindl A., Argani P., Healey J. H., Ueda T., Yoshikawa H., Meloni-Ehrig A., Sorensen P. H. B., Mertens F., Mandahl N., Van Den Berghe H., Sciot R., Dal Cin P., Bridge J., The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 Oncogene 2001 20 1 48 57 (Pubitemid 32142337)
23. Huang H. Y., Lui M. Y., Ladanyi M., Nonrandom cell-cycle timing of a somatic chromosomal translocation: the t(X;17) of alveolar soft-part sarcoma occurs in G2 Genes Chromosomes and Cancer 2005 44 2 170 176 (Pubitemid 41306645)
24. Argani P., Antonescu C. R., Illei P. B., Lui M. Y., Timmons C. F., Newbury R., Reuter V. E., Garvin A. J., Perez-Atayde A. R., Fletcher J. A., Beckwith J. B., Bridge J. A., Ladanyi M., Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents American Journal of Pathology 2001 159 1 179 192 (Pubitemid 33704203)
25. Hemesath T. J., Steingrimsson E., McGill G., Hansen M. J., Vaught J., Hodgkinson C. A., Arnheiter H., Copeland N. G., Jenkins N. A., Fisher D. E., Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family Genes and Development 1994 8 22 2770 2780 (Pubitemid 24375425)
26. Kuiper R. P., Schepens M., Thijssen J., Schoenmakers E. F. P. M., van Kessel A. G., Regulation of the MiTF/TFE bHLH-LZ transcription factors through restricted spatial expression and alternative splicing of functional domains Nucleic Acids Research 2004 32 8 2315 2322 (Pubitemid 38854786)
27. Nijman S. M., Hijmans E. M., El Messaoudi S., Van Dongen M. M. W., Sardet C., Bernards R., A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor- Journal of Biological Chemistry 2006 281 31 21582 21587 (Pubitemid 44181861)
28. Beckmann H., Su L. K., Kadesch T., TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer uE3 motif Genes and Development 1990 4 2 167 179
29. Roman C., Cohn L., Calame K., A dominant negative form of transcription activator mTFE3 created by differential splicing Science 1991 254 5028 94 97 (Pubitemid 21917323)
30. Argani P., Laé M., Ballard E. T., Amin M., Manivel C., Hutchinson B., Reuter V. E., Ladanyi M., Translocation carcinomas of the kidney after chemotherapy in childhood Journal of Clinical Oncology 2006 24 10 1529 1534 (Pubitemid 46638774)
31. Alexandru G., Graumann J., Smith G. T., Kolawa N. J., Fang R., Deshaies R. J., UBXD7 binds multiple ubiquitin ligases and implicates p97 in HIF1 turnover Cell 2008 134 5 804 816
32. Argani P., Aulmann S., Illei P. B., Netto G. J., Ro J., Cho H. Y., Dogan S., Ladanyi M., Martignoni G., Goldblum J. R., Weiss S. W., A distinctive subset of PEComas harbors TFE3 gene fusions American Journal of Surgical Pathology 2010 34 10 1395 1406
33. Weterman M. A. J., Wilbrink M., Van Kessel A. G., Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)- positive papillary renal cell carcinomas Proceedings of the National Academy of Sciences of the United States of America 1996 93 26 15294 15298
34. Sidhar S. K., Clark J., Gill S., Hamoudi R., Crew A. J., Gwilliam R., Ross M., Linehan W. M., Birdsall S., Shipley J., Cooper C. S., The t(X;1)(p11.2;q21.2) translocation in papillary renal sell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene Human Molecular Genetics 1996 5 9 1333 1338 (Pubitemid 26335852)
35. Clark J., Lu Y. J., Sidhar S. K., Parker C., Gill S., Smedley D., Hamoudi R., Linehan W. M., Shipley J., Cooper C. S., Fusion of splicing factor genes PSF and NonO (p54 nrb) to the TFE3 gene in papillary renal cell carcinoma Oncogene 1997 15 18 2233 2239 (Pubitemid 27493913)
36. Argani P., Lui M. Y., Couturier J., Bouvier R., Fournet J. C., Ladanyi M., A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23) Oncogene 2003 22 34 5374 5378 (Pubitemid 37056101)
37. Dijkhuizen T., van den Berg E., Wilbrink M., Weterman M., Van Kessel A. G., Storkel S., Folkers R. P., Braam A., De Jong B., Distinct Xp11.2 breakpoints in two renal cell carcinomas exhibiting X; autosome translocations Genes Chromosomes and Cancer 1995 14 1 43 50
38. Argani P., Olgac S., Tickoo S. K., Goldfischer M., Moch H., Chan D. Y., Eble J. N., Bonsib S. M., Jimeno M., Lloreta J., Billis A., Hicks J., De Marzo A. M., Reuter V. E., Ladanyi M., Xp11 Translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum American Journal of Surgical Pathology 2007 31 8 1149 1160 (Pubitemid 47207116)
39. Armah H. B., Parwani A. V., Surti U., Bastacky S. I., Xp11.2 translocation renal cell carcinoma occurring during pregnancy with a novel translocation involving chromosome 19: a case report with review of the literature Diagnostic Pathology 2009 4 1, article 15
40. Tsuda M., Davis I. J., Argani P., Shukla N., McGill G. G., Nagai M., Saito T., Laé M., Fisher D. E., Ladanyi M., TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition Cancer Research 2007 67 3 919 929
41. A phase 2 study of ARQ 197 in patients with microphthalmia transcription factor associated tumors. http://www.clinicaltrials.gov/show/NCT00557609
42. Goldberg J., Demetri G. D., Choy E., Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors Journal of Clinical Oncology 2009 27 15s. (suppl; abstr 10502)
43. Palassini E., Stacchiotti S., Negri T., Sunitinib malate (SM) in alveolar soft part sarcoma (ASPS) Journal of Clinical Oncology 2010 28 15s. (suppl; abstr 10014)
44. Sorafenib in Treating Patients With Soft Tissue Sarcomas. http://www.clinicaltrials.gov/ct/show/NCT00330421
45. A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas. http://www.clinicaltrials.gov/ct2/show/NCT00401388
46. Azizi A. A., Haberler C., Czech T., Gupper A., Prayer D., Breitschopf H., Acker T., Slavc I., Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma Lancet Oncology 2006 7 6 521 523 (Pubitemid 43779166)
47. Vistica D. T., Hollingshead M., Borgel S. D., Kenney S., Stockwin L. H., Raffeld M., Schrump D. S., Burkett S., Stone G., Butcher D. O., Shoemaker R. H., Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy Journal of Pediatric Hematology/Oncology 2009 31 8 561 570
48. Gardner K., Judson I., Leahy M., Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma Journal of Clinical Oncology 2009 27 15s. (suppl; abstr 10523)
49. A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS). http://www.clinicaltrials.gov/ct2/show/NCT01337401
50. Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma. http://www.clinicaltrials.gov/ct2/show/NCT00942877
51. Stockwin L. H., Vistica D. T., Kenney S., Schrump D. S., Butcher D. O., Raffeld M., Shoemaker R. H., Gene expression profiling of alveolar soft-part sarcoma (ASPS) BMC Cancer 2009 9 22
52. Lazar A. J., Das P., Tuvin D., Korchin B., Zhu Q., Jin Z., Warneke C. L., Zhang P. S., Hernandez V., Lopez-Terrada D., Pisters P. W., Pollock R. E., Lev D., Angiogenesis-promoting gene patterns in alveolar soft part sarcoma Clinical Cancer Research 2007 13 24 7314 7321
53. Kerzerho J., Adotevi O., Castelli F. A., Dosset M., Bernardeau K., Szely N., Lang F., Tartour E., Maillere B., The angiogenic growth factor and biomarker midkine is a tumor-shared antigen Journal of Immunology 2010 185 1 418 423
54. van der Horst E. H., Frank B. T., Chinn L., Coxon A., Li S., Polesso F., Slavin A., Ruefli-Brasse A., Wesche H., The growth factor midkine antagonizes VEGF signaling in vitro and in vivo Neoplasia 2008 10 4 340 346 (Pubitemid 351483573)
55. Benedito R., Roca C., Srensen I., Adams S., Gossler A., Fruttiger M., Adams R. H., The notch ligands Dll4 and jagged1 have opposing effects on angiogenesis Cell 2009 137 6 1124 1135
56. Dufraine J., Funahashi Y., Kitajewski J., Notch signaling regulates tumor angiogenesis by diverse mechanisms Oncogene 2008 27 38 5132 5137
57. Steg A. D., Katre A. A., Goodman B., Han H.-D., Nick A. M., Stone R. L., Coleman R. L., Alvarez R. D., Lopez-Berestein G., Sood A. K., Landen C. N., Targeting the Notch ligand jagged1 in both tumor cells and stroma in ovarian cancer Clinical Cancer Research 2011 17 17 5674 5685
58. Maldonado A. R., Klanke C., Jegga A. G., Aronow B. J., Mahller Y. Y., Cripe T. P., Crombleholme T. M., Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors Journal of Gene Medicine 2010 12 7 613 623
59. Adachi Y., Reynolds P. N., Yamamoto M., Grizzle W. E., Overturf K., Matsubara S., Muramatsu T., Curiel D. T., Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors Cancer Research 2000 60 16 4305 4310 (Pubitemid 32103599)
60. Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer. http://www.clinicaltrials.gov/ct2/show/NCT00704158
61. A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma. http://www.clinicaltrials.gov/ct2/show/NCT00412828
62. Martignoni G., Gobbo S., Camparo P., Differential expression of cathpsin K in neoplasms harboring TFE3 gene fusions Modern Pathology 2011 24 10 1313 1319
63. Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD). http://www.clinicaltrials.gov/ct/ show/NCT00399802